View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 2, 2022

ProJenX doses first subject in Phase I ALS trial

The trial will assess prosetin’ safety, tolerability, pharmacokinetics and pharmacodynamics in healthy subjects and ALS patients.

ProJenX has dosed the first subject in the first-in-human Phase 1 PRO-101 clinical trial of its investigational new drug, prosetin, in healthy subjects and amyotrophic lateral sclerosis (ALS) patients.

An oral, brain-penetrant, mitogen-activated protein kinase kinase kinase kinase (MAP4K) inhibitor, prosetin acts on endoplasmic reticulum (ER) stress. 

ER stress is a common characteristic of ALS’ sporadic and familial forms.

In a patient-specific, cell-based discovery platform developed by Columbia University scientists, MAP4Ks were detected as the crucial ER stress-mediated motor neuron loss regulators.

The three-part, hybrid trial will analyse the safety, tolerability, pharmacokinetics and pharmacodynamics of the drug in healthy subjects and individuals with ALS.

Parts 1a and 1b will be double-blind, randomised, placebo-controlled, dose-escalating studies for assessing the safety, tolerability and pharmacokinetics of single ascending and multiple doses of prosetin in healthy subjects. 

On evaluating data from these parts, Part 1c of the trial will assess the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with ALS.

The PRO-101 trial was designed following talks with the Food and Drug Administration (FDA), various clinicians and community advisors for ALS.

It seeks to validate the safety and biomarker data required for selecting the dose and designing late-stage trials. 

ProJenX co-founder and Operations senior director Erin Fleming said: “We are excited to advance prosetin, a potential first-in-class treatment for ALS and related neurodegenerative diseases, into the clinic. 

“PRO-101 will provide essential safety, pharmacokinetic, and biomarker data about prosetin to inform our decisions on future clinical testing, including potential registrational studies.” Project ALS, a nonprofit organisation funded the preclinical development of prosetin. 

Clinical Trials Arena previously looked into how to build a clinical trial in ALS for approval.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy